Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone vs Baclofen for Alcohol Abstinence in Liver Cirrhosis
NCT06175507Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of naltrexone in alcohol dependence (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Proportion of patients achieving and maintaining alcohol abstinence at 12 weeks. Status: unknown.
02
Drugs
naltrexone
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on NCT06175507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175507.